Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Oct 24;42(1):179–187. doi: 10.3892/ijo.2012.1675

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2013, Spandidos Publications

This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.

PMC Copyright notice

Figure 1. — YC-1 inhibits cell viability and progestin-induced VEGF secretion in human breast cancer cells (n=6 for each concentration). (A), T47-D and BT-474 cells were treated with indicated concentrations of YC-1 for 18 h and cell viability was determined using the SRB assay. ^*Significantly different from control (p<0.001, ANOVA). (B), T47-D cells were pre-treated for 30 min with 1 μM RU-486, or 100 μM YC-1 and then treated with 10 nM progesterone or MPA or with synthetic progestins (C). Media was collected after 16–18 h and analyzed for VEGF using ELISA as described in Materials and methods (n=3–12). One-way ANOVA was used to statistically analyze data. ^*Significant induction compared with control. ^**Significant inhibition compared with appropriate progestin control, p<0.05. The control value for VEGF in Fig. 2A represents 496±51 pg/mg cellular protein.

Figure 1. — YC-1 inhibits cell viability and progestin-induced VEGF secretion in human breast cancer cells (n=6 for each concentration). (A), T47-D and BT-474 cells were treated with indicated concentrations of YC-1 for 18 h and cell viability was determined using the SRB assay. ^*Significantly different from control (p<0.001, ANOVA). (B), T47-D cells were pre-treated for 30 min with 1 μM RU-486, or 100 μM YC-1 and then treated with 10 nM progesterone or MPA or with synthetic progestins (C). Media was collected after 16–18 h and analyzed for VEGF using ELISA as described in Materials and methods (n=3–12). One-way ANOVA was used to statistically analyze data. ^*Significant induction compared with control. ^**Significant inhibition compared with appropriate progestin control, p<0.05. The control value for VEGF in Fig. 2A represents 496±51 pg/mg cellular protein.